Responses
Clinical/translational cancer immunotherapy
Original research
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
